Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease

NCT03240731 is registered in ClinicalTrials.gov with Centre Hospitalier Intercommunal Creteil as lead sponsor.

NCT NCT03240731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03240731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease
Lead sponsor
Centre Hospitalier Intercommunal Creteil
Phase
Phase 2
Overall status
Completed
Start date
August 10, 2017
Completion date
April 8, 2024
Enrollment
25 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease